Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: A randomized study with long-term follow-up

British Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 115-122

  Bontenbal, M ^a   Foekens, J A ^a   Lamberts, S W J ^b   De Jong, F H ^b   Van Putten, W L J ^a   Braun, H J ^c   Burghouts, J Th M ^d   Van Der Linden, G H M ^e   Klijn, J G M ^a,f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Department of Microbiology   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e Refaja Ziekenhuis Stadskanaal   (Netherlands)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Anti prolactin; Breast cancer; GH IGF 1 axis: somatostatin analogue

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE; INSULIN; OCTREOTIDE; QUINAGOLIDE; SOMATOMEDIN C; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031964609     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.18     Document Type: Article

References (77)

1. Alexieva-Figusch J, Blankenstein MA, Hop WCJ, Klijn JGM, Lamberts SWJ, de Jong FH, Docter R, Adlercreutz H and van Gilse HA (1984) Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects. Eur J Cancer Clin Oncol 20: 33-40
2. Arteaga CL and Osborne CK (1989) Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49: 6237-6241
3. Bogden AE, Keyes SR, Grant W, Zwicker S, Silver M, Batista IL and Lepage D (1995) Therapeutic benefit of a lanreotide-tamoxifen combination in the treatment of breast tumors. Proc Am Assoc Cancer Res 36:1507A
4. Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, Sevin M, Chollet P and Cappelaere P (1988) Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double-blind multicentre clinical trial. Eur J Cancer Clin Oncol 24: 1851-1853
5. Bonneterre J, Peyrat JP, Beuscart R and Demaille A (1990) Biological and clinical aspects of prolactin receptors (PRL-R) in human breast cancer. J Steroid Biochem Molec Biol 37: 977-981
6. Buscail L, Estève JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N and Susini C (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci 92: 1580-1584
7. Butta A, Maclennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M and Colletta AA (1992) Induction of transforming growth factor β in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264
8. Chiodera P, Volpi R, D'Amato L, Fatone M, Cigarini C, Fava A, Caiazza A, Rossi G and Coiro V (1986) Inhibition by somatostatin of LH-RH-induced LH release in normal menstruating women. Gynaecol Obstet Invest 22: 17-21
9. Clarke R, Dickson RB and Lippman ME (1992) Hormonal aspects of breast cancer: growth factors, drugs and stromal interactions. Crit Rev Oncol/Hematol 12: 1-23
10. Coletti RB, Roberts JD, Devlin JT and Copeland KC (1989) Effects of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49: 1882-1884
11. Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N and Zwiebel JA (1992) Insulin-like growth factor-II expression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 6: 91-100
12. Davoren JB and Hsueh AJW (1986) Growth hormone increases ovarian levels of immunoreactive somatomedin C/insulin-like growth factor I in vivo. Endocrinol 118: 888-890
13. Dogliotti L, Robustelli Delle Cuna G, Di Carlo F and Brompa Italian Coop Group (1987) Medroxyprogesterone acetate high-dose (MPA-MD) versus MPA-HD plus bromocriptine in advanced breast cancer: preliminary results of a multicentre randomized clinical trial. In Hormonal Manipulation of Cancer: Peptides. Growth Factors and New Anti (Steroidal) Agents. EORTC Monograph Series, 18 Klijn, JGM and Paridaens R and Foekens JA (eds), pp. 183-193. New York: Raven Press
14. Emerman JT, Leaky M, Gout PW and Bruchovsky N (1985) Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res 17: 421-424
15. Engelsman E, Heuson JC, Blonk-Van Der Wijst J, Drochmans A, Maass H, Cheix F, Sobrinho LG and Nowakowski N (1975) Controlled clinical trials of L-dopa and nafoxidine in advanced breast cancer: an EORTC study. Br Med J 2: 714-715
16. European Breast Cancer Group (1972) Clinical trial of 2-Br-α-ergocryptine (CB-154) in advanced breast cancer. Eur J Cancer 8: 155-156
17. van Eijck CHJ, Krenning EP, Bootsma A, Oei HY, Van Pel R, Lindemans J, Jeekel J, Reubi JC and Lamberts SWJ (1994) Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343: 640-643
18. 6]-luteinizing-hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Analysis 3: 137-141
19. Fentimen IS, Brame K, Chaudary MA, Champlejohn RS, Wang DY and Millis RR (1988) Perioperative bromocriptine adjuvant treatment for operable breast cancer. Lancet 1: 609-610
20. Fields K, Kulig E and Lloyd RV (1993) Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab Invest 68: 354-360
21. Foekens JA, Portengen H, Van Putten WLJ, Reubi JC, Trapman AMAC, Alexieva-Figusch J and Klijn JGM (1989) The prognostic significance of receptors for insulin-like growth factor-I, somatostatin, and epidermal growth factor in human primary breast cancer. Cancer Res 49: 7002-7009
22. Foekens JA, Portengen H, Janssen M and Klijn JGM (1989b) Insulin-like growth factor-I-receptors and insulin-like growth factor-I-like activity in human primary breast cancer. Cancer 63: 2139-2147
23. Freiss G, Rochefort H and Vignon F (1990) Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alteration of growth factor receptor binding sites and tyrosine kinase activity. Biochem Biophys Res Commun 173: 919-926
24. Ginsburg E and Vonderhaar BK (1995) Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 55: 2591-2595
25. Grisoli F, Vincentelli F, Foa J, Lavail G and Salamon G (1981) Effect of bromocriptine on brain metastasis in breast cancer. Lancet 2: 745-746
26. Holtkamp W, Nagel GE, Wander HE, Rauschecker HF and Von Heyden D (1984) Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 34: 323-328
27. Holtkamp W and Nagel GA (1990) Remission of metastatic breast cancer after combined somatostatin and antiprolactin treatment. Eur J Cancer 26: 177
28. Huynh H and Pollak M (1994) Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 203: 253-259
29. Kelly PA, Djiane J, Postel-Vinay MC and Edery M (1991) The prolactin/growth hormone receptor family. Endocrine Rev 12: 235-251
30. Kiang DT, Kollander R, Kiang B and Kao PC (1992) Role of plasma IGF-I in endocrine therapy for breast cancer (abstract 31). Proc Am Soc Clin Oncol 11: 51
31. Klijn JGM, De Jong FH, Lamberts SWJ and Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867-878
32. Klijn JGM, Hoff AM, Planting ASTH, Verweij J, Kok TC, Lamberts SWJ, Portengen H and Foekens JA (1990a) Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analog Sandostatin: A phase II study including endocrine effects. Br J Cancer 62: 627-630
33. Klijn JGM, Setyono-Han B, Bakker GH, Van Der Burg MEL, Bontenbal M, Peters HA, Sieuwerts AM, Berns PMJJ and Foekens JA (1990b) Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies. J Steroid Biochem Molec Biol 37: 1089-1095
34. Klijn JGM, Berns PMJJ, Bontenbal M, Alexieva-Figusch J and Foekens JA (1992) Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Molec Biol 43: 211-221
35. Klijn JGM, Berns PMJJ and Foekens JA (1993) Prognostic factors and response to therapy in breast cancer. Cancer Surv 18: 165-198
36. Kopp A, Jonat W, Schmall M and Knabbe C (1995) Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55: 4512-4515
37. Lamberts SWJ and Macleod RM (1990) Regulation of prolactin secretion at the level of the lactotroph. Physiolog Rev 70: 279-318
38. Lamberts SWJ, Krenning EP and Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 12: 450-482
39. Lamberts SWJ, Van Der Lely AJ, De Herder WW and Hofland LJ (1996) Octreotide. N Engl J Med 334: 246-254
40. Lönning PE, Hall K, Aakvaag A and Lien EA (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein 1 in breast cancer patients. Cancer Res 52: 4719-4723
41. Malaab SA, Pollak MN and Goodyer CG (1992) Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A: 788-793
42. Malarkey WB, Kennedy M, Allred LE and Milo G (1983) Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 56: 673-677
43. Manni A, Wright C, Davis G, Glenn J, Joehl R and Feil P (1986) Promotion by prolactin of the growth of human breast neoplasms cultured in vitro in the soft agar clonogenic assay. Cancer Res 46: 1668-1672
44. Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA and Bartholomew M (1989) Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14: 289-298
45. Mershon J, Sall W, Mitchner N and Ben-Jonathan N (1995) Prolactin is a local growth factor in rat mammary tumors. Endocrinology 136: 3619-3623
46. Minton JP (1974) The response of breast cancer patients with bone pain to L-dopa. Cancer 33: 358-363
47. Mol JA, Van Garderen E, Selman PJ, Wolfswinkel J, Rijnberk A and Rutteman GR (1995) Growth hormone mRNA in mammary gland tumors of dogs and cats. J Clin Invest 95: 2028-2034
48. Morten H, Howell A, Shalet SM, Robinson L and Anderson E (1988) Measurement of immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and SMS 201-995. J Endocrinol 119S
49. Murphy LJ, Vrhovsek E, Sutherland RL and Lazarus L (1984) Growth hormone binding to cultured human breast cancer cells. J Clin Endocrinol Metab 58: 149-156
50. Osborne CK, Clemmons DR and Arteaga CL (1990) Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Molec Biol 37: 805-809
51. Pekonen F, Partanen S, Mäkinen T and Rutanen EM (1988) Receptors for epidermal growth factor and insulin-like growth factor-I and their relation to steroid receptors in human breast cancer. Cancer Res 48: 1343-1347
52. Peyrat JP, Bonneterre J, Beuscart B, Djiane J and Demaille A (1988a) Insulin-like growth factor-I receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48: 6424-6433
53. Peyrat JP, Bonneterre J, Laurent JC, Louchez MM, Amrani S, Leroy-Martin B, Vilain MO, Delobelle A and Demaille A (1988b) Presence and characterisation of insulin-like growth factor-I receptors in benign breast diseases. Eur J Cancer Clin Oncol: 24: 1425-1431
54. Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez, MM, Fournier C, Lefebvre J and Demaille A (1993) Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 29A: 492-497
55. Pollak MN, Polychronakos C and Yousefi S (1988) Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154: 326-331
56. Pollak MN, Polychronakos C and Guyda H (1989) Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9: 889-891
57. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, Fisher B and Margolese R (1990) Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697
58. Pollak MN, Huynh T, Pratt H and Lefebvre S (1992) Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22: 91-100
59. Pratt SE and Pollak MN (1993) Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-5198
60. Prévost G, Hosford D and Thomas F (1994) Receptors for somatostatin and somatostatin analogues in human breast tumors. Ann NY Acad Sci 133: 147-154
61. Rasmussen C, Bergh T, Wide L and Brownell J (1987) CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol 26: 321-326
62. Reed MJ, Christodoulides A, Koistinen R, Seppälä M, Teale JB and Ghilchik MW (1992) The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-I in women with advanced breast cancer. Int J Cancer 52: 208-212
63. Reubi JC, Waser B, Fockens JA, Klijn JGM, Lamberts SWJ and Laissue J (1990) Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography. Relationship to EGF receptors. Int J Cancer 46: 416-420
64. Van Roozendaal CEP, Klijn JGM, Van Ooijen B, Claassen C, Eggermont AMM, Henzen-Logmans SC and Foekens JA (1995) Transforming growth factor beta secretion from primary breast cancer fibroblasts. Mol Cell Endocrinol 111: 1-6
65. Rose DP, Gottardis M and Noonan JJ (1983) Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin. Anticancer Res 3: 323
66. Santen RJ, Manni A, Harvey H and Redmond C (1990) Endocrine treatment of breast cancer in women. Endocrine Rev 11: 221-265
67. Schally AV, Redding TW, Cai RZ, Paz JI, Ben-David M and Comaru-Schally AM (1987) Somatostatin analogs in the treatment of various experimental tumors. In Hormonal Manipulation of Cancer: Peptides, Growth Factors and new Anti (steroidal) Agents. Monograph Series of the EORTC, Vol. 18, Klijn JGM, Paridaens R and Foekens JA (eds), pp. 431-441. New York: Raven Press
68. Schally AV (1988) Oncological applications of somatostatin analogues. Cancer Res 48: 6977-6985
69. Setyono-Han B, Henkelman MS, Foekens JA and Klijn JGM (1987) Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566-1570
70. Srkalovic G, Cai RZ and Schally AV (1990) Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab 70: 661-669
71. Szende B, Lapis K, Redding TW, Srkalovic G and Schally AV (1989) Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Res Treat 14: 307-314
72. Tannenbaum SG, Gurd W, Lapointe M and Pollak M (1992) Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130: 3395-3401
73. Vennin P, Peyrat JP, Bonneterre J, Louchez MM, Harris AG and Demaille A (1989) Effect of the long-acting somatostatin analog SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 9: 153-156
74. Weber C, Merriam L, Kotschitzky T, Kar PF, Benson M, Forde K and Logerfo P (1989) Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery 106: 416-422
75. Weckbecker G, Liu R, Tolcsvai L and Bruns C (1992) Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 52: 4973-4978
76. Weckbecker G, Tolcsvai L, Stolz B, Pollak M and Bruns C (1994) Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-Dimethylbenz(α)anthracene-induced rat mammary carcinomas. Cancer Res 54: 6334-6337
77. Winston R, Kao PC and Kiang DT (1994) Regulation of insulin-like growth factors by antiestrogen. Breast Cancer Res Treat 31: 107-115